In 1998, American scientists Andrew Fire and Craig Mello published their discovery of a mechanism that can degrade mRNA from a specific gene – essentially silencing the gene. The discovery was so ...

The recent purchase by Worcester-based RXi Pharmaceuticals of a company specializing in cancer therapies has some wondering if the company is moving away from its bread-and-butter technology, which ...

Adds $16.6 million in revenue and increases CloudMD’s current annualized run-rate to over $60 million Rxi’s pharmaceutical logistic services include drug distribution, patient navigation assistance, a ...

WESTBOROUGH, Mass., June 6, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies ...

CytRx Corporation's 45% Owned Affiliate RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therapeutics from the University of Massachusetts Medical ...

Please provide your email address to receive an email when new articles are posted on . RXi Pharmaceuticals Corporation announced it has received a U.S. patent issuance for its compromised skin ...

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today ...

WESTBOROUGH, Mass. & MIAMI--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing ...

VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a healthcare technology company ...

RXi Pharmaceuticals Corporation announced that it has exercised its option to an exclusive worldwide license to novel technologies from Advirna LLC to enable in vivo delivery of RNAi therapeutics.